CHEMOCENTRYX
ChemoCentryxis a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx focuses on the discovery, development, and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. The company's small molecule product candidates are designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.
CHEMOCENTRYX
Industry:
Biotechnology Health Care Medical Device
Founded:
1997-01-01
Address:
San Carlos, California, United States
Country:
United States
Website Url:
http://www.chemocentryx.com
Total Employee:
101+
Status:
Active
Contact:
+1.650.210.2900
Total Funding:
634.34 M USD
Technology used in webpage:
SPF SSL By Default Mobile Non Scaleable Content Amazon IPv6 Google Maps ReCAPTCHA Microsoft Azure DNS Google Maps API Apple Mobile Web App Capable
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Gelesis
Gelesis is a biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients.
Intarcia Therapeutics
Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
Myomo
Myomo develops devices with myoelectric prosthetic technology to restore the mobility of individuals with muscle weakness.
Current Advisors List
Board_member
Current Employees Featured
Rita I. Jain EVP & Chief Medical Officer @ ChemoCentryx
EVP & Chief Medical Officer
2021-10-01
Sangita Ghosh Senior Vice President, Technical Operations @ ChemoCentryx
Senior Vice President, Technical Operations
Markus J. Cappel Chief Business Officer and Treasurer @ ChemoCentryx
Chief Business Officer and Treasurer
Dalia Rayes Senior Vice President, Head of Commercial @ ChemoCentryx
Senior Vice President, Head of Commercial
Susan M. Kanaya Senior Vice President, Finance, Chief Financial Officer and Secretary @ ChemoCentryx
Senior Vice President, Finance, Chief Financial Officer and Secretary
Gopi Kurse Vice President, Quality @ ChemoCentryx
Vice President, Quality
2020-06-01
Kari Leetch Senior Vice President, Human Resources @ ChemoCentryx
Senior Vice President, Human Resources
Thomas J. Schall Founder, President, Chief Executive Officer and Chairman of the Board @ ChemoCentryx
Founder, President, Chief Executive Officer and Chairman of the Board
Catherine L. Kelleher Senior Vice President, Clinical Development @ ChemoCentryx
Senior Vice President, Clinical Development
2019-01-01
Jan L Hillson Senior Vice President, Drug Development @ ChemoCentryx
Senior Vice President, Drug Development
2016-01-01
Founder
Stock Details
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - ChemoCentryx
Alta Partners
Alta Partners investment in Series E - ChemoCentryx
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series E - ChemoCentryx
Glaxo Group
Glaxo Group investment in Series E - ChemoCentryx
HealthCap
HealthCap investment in Series E - ChemoCentryx
Glaxo Group
Glaxo Group investment in Series D - ChemoCentryx
OrbiMed
OrbiMed investment in Series D - ChemoCentryx
Gimv
Gimv investment in Series D - ChemoCentryx
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series D - ChemoCentryx
Alta Partners
Alta Partners investment in Series D - ChemoCentryx
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-11 | ChemoCentryx Appoints Rita I. Jain, M.D. as Executive Vice President, Chief Medical Officer |
Official Site Inspections
http://www.chemocentryx.com Semrush global rank: 4.64 M Semrush visits lastest month: 2.14 K
- Host name: cloudproxy10158.sucuri.net
- IP address: 192.124.249.158
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "ChemoCentryx"
ChemoCentryx, Inc. Company Profile - Dun & Bradstreet
Company Description: ChemoCentryx is an integrated United States biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases …See details»
ChemoCentryx, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for ChemoCentryx, Inc. of Thousand Oaks, CA. Get the latest business insights from Dun & …See details»
ChemoCentryx Company Profile - Office Locations, Competitors
Mar 3, 2022 ChemoCentryx is a biopharmaceutical company commercializing and developing medications for inflammatory and autoimmune diseases and cancer. It focuses on orphan and …See details»
Chemocentryx Company Profile 2025: Valuation, …
When was Chemocentryx founded? Chemocentryx was founded in 1997. Where is Chemocentryx headquartered? Chemocentryx is headquartered in Mountain View, CA. What is the size of Chemocentryx? Chemocentryx has 178 total …See details»
ChemoCentryx, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
ChemoCentryx is a biopharmaceutical corporation that specializes in creating innovative medications for the treatment of inflammatory and autoimmune diseases, as well as cancer. …See details»
ChemoCentryx - Products, Competitors, Financials, Employees ...
ChemoCentryx was founded in 1997. Where is ChemoCentryx's headquarters? ChemoCentryx's headquarters is located at 850 Maude Avenue, Mountain View. What is ChemoCentryx's latest …See details»
ChemoCentryx Inc Company Profile - GlobalData
ChemoCentryx Inc (ChemoCentryx) is a bio pharmaceutical company that discovers, develops and commercializes orally-administered therapeutics for the treatment of cancer, autoimmune …See details»
ChemoCentryx - Funding, Financials, Valuation & Investors
ChemoCentryx is a biopharmaceutical company that develops medications for inflammatory and autoimmune diseases and cancer. Search Crunchbase. Start Free Trial . ... How much funding …See details»
ChemoCentryx, Inc. - VentureRadar
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory …See details»
ChemoCentryx Notification - Amgen
ChemoCentryx Notification. Main Menu ; About. Overview Amgen History Mission and Values Leadership Amgen Foundation . Awards and Accolades ...See details»
ChemoCentryx CEO and Key Executive Team | Craft.co
ChemoCentryx's President, Chief Executive Officer and Chairman of the Board is Thomas J. Schall. Other executives include Susan M. Kanaya, Executive Vice President, Chief Financial …See details»
ChemoCentryx, Inc. | Scientist.com
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory …See details»
ChemoCentryx - Contacts, Employees, Board Members, Advisors
Organization. ChemoCentryx . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... including EVP & Chief Medical Officer Rita …See details»
ChemoCentryx, Inc. Locations - Contract Research Map
850 Maude Ave. Mountain View, CA 94043 ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to …See details»
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF …
Oct 20, 2022 TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio. THOUSAND OAKS, Calif., Oct. …See details»
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
Aug 4, 2022 Acquisition Includes TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Serious Autoimmune Disease . Tavneos Adds to Amgen 's Decades-Long Leadership in …See details»
Amgen to Acquire ChemoCentryx for $3.7B, Bolstering …
Aug 5, 2022 Last month, ChemoCentryx presented positive safety results from the first 13 patients enrolled across four dose cohorts: (30 mg, 60 mg, 120 mg, and 180 mg) as of April …See details»
Amgen bets on ChemoCentryx's rare disease drug in $3.7 billion deal
Aug 4, 2022 The company, which kept its full-year adjusted profit forecast unchanged at between $17 and $18 per share, would pay $52 in cash for each share of ChemoCentryx, a …See details»
ChemoCentryx - Tech Stack, Apps, Patents & Trademarks
Dec 29, 2024 ChemoCentryx uses 25 technology products and services including HTML5, Lightbox, and Microsoft Outlook, according to G2 Stack. ChemoCentryx is actively using 25 …See details»
FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION …
5 hours ago Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC. THOUSAND OAKS, Calif., Jan. 17, 2025 …See details»